Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2000 Apr;59(4):243–251. doi: 10.1136/ard.59.4.243

Cytokines and systemic lupus erythematosus

G Dean 1, J Tyrrell-Price 1, E Crawley 1, D Isenberg 1
PMCID: PMC1753117  PMID: 10733469

Full Text

The Full Text of this article is available as a PDF (147.1 KB).

Figure 1  .

Figure 1  

Open in a new tab

Summary of abnormal cytokine profiles in skin, kidney and neurological systems.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abraham L. J., French M. A., Dawkins R. L. Polymorphic MHC ancestral haplotypes affect the activity of tumour necrosis factor-alpha. Clin Exp Immunol. 1993 Apr;92(1):14–18. doi: 10.1111/j.1365-2249.1993.tb05940.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Alcocer-Varela J., Aleman-Hoey D., Alarcon-Segovia D. Interleukin-1 and interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T-cell activation markers. Lupus. 1992 Feb;1(2):111–117. doi: 10.1177/096120339200100209. [DOI] [PubMed] [Google Scholar]
  3. Barcellini W., Rizzardi G. P., Borghi M. O., Nicoletti F., Fain C., Del Papa N., Meroni P. L. In vitro type-1 and type-2 cytokine production in systemic lupus erythematosus: lack of relationship with clinical disease activity. Lupus. 1996 Apr;5(2):139–145. doi: 10.1177/096120339600500209. [DOI] [PubMed] [Google Scholar]
  4. Bienvenu J., Doche C., Gutowski M. C., Lenoble M., Lepape A., Perdrix J. P. Production of proinflammatory cytokines and cytokines involved in the TH1/TH2 balance is modulated by pentoxifylline. J Cardiovasc Pharmacol. 1995;25 (Suppl 2):S80–S84. doi: 10.1097/00005344-199500252-00017. [DOI] [PubMed] [Google Scholar]
  5. Braude I. A., Hochberg M. C., Arnett F. C., Waldmann T. A. In vitro suppression of anti-DNA antibody and immunoglobulin synthesis in systemic lupus erythematosus patients by human gamma interferon. J Rheumatol. 1988 Mar;15(3):438–444. [PubMed] [Google Scholar]
  6. Brennan D. C., Yui M. A., Wuthrich R. P., Kelley V. E. Tumor necrosis factor and IL-1 in New Zealand Black/White mice. Enhanced gene expression and acceleration of renal injury. J Immunol. 1989 Dec 1;143(11):3470–3475. [PubMed] [Google Scholar]
  7. Casciola-Rosen L., Rosen A. Ultraviolet light-induced keratinocyte apoptosis: a potential mechanism for the induction of skin lesions and autoantibody production in LE. Lupus. 1997;6(2):175–180. doi: 10.1177/096120339700600213. [DOI] [PubMed] [Google Scholar]
  8. Cherwinski H. M., Schumacher J. H., Brown K. D., Mosmann T. R. Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies. J Exp Med. 1987 Nov 1;166(5):1229–1244. doi: 10.1084/jem.166.5.1229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cobbold S., Waldmann H. Infectious tolerance. Curr Opin Immunol. 1998 Oct;10(5):518–524. doi: 10.1016/s0952-7915(98)80217-3. [DOI] [PubMed] [Google Scholar]
  10. Crawley E., Woo P., Isenberg D. A. Single nucleotide polymorphic haplotypes of the interleukin-10 5' flanking region are not associated with renal disease or serology in Caucasian patients with systemic lupus erythematosus. Arthritis Rheum. 1999 Sep;42(9):2017–2018. doi: 10.1002/1529-0131(199909)42:9<2017::AID-ANR34>3.0.CO;2-I. [DOI] [PubMed] [Google Scholar]
  11. D'Alfonso S., Richiardi P. M. A polymorphic variation in a putative regulation box of the TNFA promoter region. Immunogenetics. 1994;39(2):150–154. doi: 10.1007/BF00188619. [DOI] [PubMed] [Google Scholar]
  12. Davas E. M., Tsirogianni A., Kappou I., Karamitsos D., Economidou I., Dantis P. C. Serum IL-6, TNFalpha, p55 srTNFalpha, p75srTNFalpha, srIL-2alpha levels and disease activity in systemic lupus erythematosus. Clin Rheumatol. 1999;18(1):17–22. doi: 10.1007/s100670050045. [DOI] [PubMed] [Google Scholar]
  13. Desai-Mehta A., Lu L., Ramsey-Goldman R., Datta S. K. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest. 1996 May 1;97(9):2063–2073. doi: 10.1172/JCI118643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Elenitsas R., Abell E., Lee Y. Y., Huang J., Deng J. S. Comparison of IgG subclass autoantibodies in patients with systemic lupus erythematosus and subacute cutaneous lupus erythematosus. J Dermatol Sci. 1990 May;1(3):207–215. doi: 10.1016/0923-1811(90)90133-x. [DOI] [PubMed] [Google Scholar]
  15. Emilie D., Llorente L., Galanaud P. Cytokines et lupus. Ann Med Interne (Paris) 1996;147(7):480–484. [PubMed] [Google Scholar]
  16. Emlen W., Niebur J., Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol. 1994 Apr 1;152(7):3685–3692. [PubMed] [Google Scholar]
  17. Eskdale J., Kube D., Tesch H., Gallagher G. Mapping of the human IL10 gene and further characterization of the 5' flanking sequence. Immunogenetics. 1997;46(2):120–128. doi: 10.1007/s002510050250. [DOI] [PubMed] [Google Scholar]
  18. Eskdale J., Wordsworth P., Bowman S., Field M., Gallagher G. Association between polymorphisms at the human IL-10 locus and systemic lupus erythematosus. Tissue Antigens. 1997 Jun;49(6):635–639. doi: 10.1111/j.1399-0039.1997.tb02812.x. [DOI] [PubMed] [Google Scholar]
  19. Funauchi M., Sugishima H., Minoda M., Horiuchi A. Effect of interferon-gamma on B lymphocytes of patients with systemic lupus erythematosus. J Rheumatol. 1991 Mar;18(3):368–372. [PubMed] [Google Scholar]
  20. Gabay C., Cakir N., Moral F., Roux-Lombard P., Meyer O., Dayer J. M., Vischer T., Yazici H., Guerne P. A. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol. 1997 Feb;24(2):303–308. [PubMed] [Google Scholar]
  21. Georgescu L., Vakkalanka R. K., Elkon K. B., Crow M. K. Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand. J Clin Invest. 1997 Nov 15;100(10):2622–2633. doi: 10.1172/JCI119806. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Gilad R., Lampl Y., Eshel Y., Barak V., Sarova-Pinhas I. Cerebrospinal fluid soluble interleukin-2 receptor in cerebral lupus. Br J Rheumatol. 1997 Feb;36(2):190–193. doi: 10.1093/rheumatology/36.2.190. [DOI] [PubMed] [Google Scholar]
  23. Grammer A. C., Bergman M. C., Miura Y., Fujita K., Davis L. S., Lipsky P. E. The CD40 ligand expressed by human B cells costimulates B cell responses. J Immunol. 1995 May 15;154(10):4996–5010. [PubMed] [Google Scholar]
  24. Haas C., Ryffel B., Le Hir M. IFN-gamma receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB x NZW)F1 mice. J Immunol. 1998 Apr 15;160(8):3713–3718. [PubMed] [Google Scholar]
  25. Hajeer A. H., Worthington J., Davies E. J., Hillarby M. C., Poulton K., Ollier W. E. TNF microsatellite a2, b3 and d2 alleles are associated with systemic lupus erythematosus. Tissue Antigens. 1997 Mar;49(3 Pt 1):222–227. doi: 10.1111/j.1399-0039.1997.tb02742.x. [DOI] [PubMed] [Google Scholar]
  26. Hefeneider S. H., Cornell K. A., Brown L. E., Bakke A. C., McCoy S. L., Bennett R. M. Nucleosomes and DNA bind to specific cell-surface molecules on murine cells and induce cytokine production. Clin Immunol Immunopathol. 1992 Jun;63(3):245–251. doi: 10.1016/0090-1229(92)90229-h. [DOI] [PubMed] [Google Scholar]
  27. Herrera-Esparza R., Barbosa-Cisneros O., Villalobos-Hurtado R., Avalos-Díaz E. Renal expression of IL-6 and TNFalpha genes in lupus nephritis. Lupus. 1998;7(3):154–158. doi: 10.1191/096120398678919949. [DOI] [PubMed] [Google Scholar]
  28. Horii Y., Iwano M., Hirata E., Shiiki M., Fujii Y., Dohi K., Ishikawa H. Role of interleukin-6 in the progression of mesangial proliferative glomerulonephritis. Kidney Int Suppl. 1993 Jan;39:S71–S75. [PubMed] [Google Scholar]
  29. Horwitz D. A., Gray J. D., Behrendsen S. C., Kubin M., Rengaraju M., Ohtsuka K., Trinchieri G. Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus. Arthritis Rheum. 1998 May;41(5):838–844. doi: 10.1002/1529-0131(199805)41:5<838::AID-ART10>3.0.CO;2-S. [DOI] [PubMed] [Google Scholar]
  30. Horwitz D. A., Gray J. D., Ohtsuka K., Hirokawa M., Takahashi T. The immunoregulatory effects of NK cells: the role of TGF-beta and implications for autoimmunity. Immunol Today. 1997 Nov;18(11):538–542. doi: 10.1016/s0167-5699(97)01149-3. [DOI] [PubMed] [Google Scholar]
  31. Horwitz D. A., Jacob C. O. The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications. Springer Semin Immunopathol. 1994;16(2-3):181–200. doi: 10.1007/BF00197516. [DOI] [PubMed] [Google Scholar]
  32. Houssiau F. A., Lefebvre C., Vanden Berghe M., Lambert M., Devogelaer J. P., Renauld J. C. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus. 1995 Oct;4(5):393–395. doi: 10.1177/096120339500400510. [DOI] [PubMed] [Google Scholar]
  33. Huang Y. P., Perrin L. H., Miescher P. A., Zubler R. H. Correlation of T and B cell activities in vitro and serum IL-2 levels in systemic lupus erythematosus. J Immunol. 1988 Aug 1;141(3):827–833. [PubMed] [Google Scholar]
  34. Jacob C. O., Fronek Z., Lewis G. D., Koo M., Hansen J. A., McDevitt H. O. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci U S A. 1990 Feb;87(3):1233–1237. doi: 10.1073/pnas.87.3.1233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Jara L. J., Irigoyen L., Ortiz M. J., Zazueta B., Bravo G., Espinoza L. R. Prolactin and interleukin-6 in neuropsychiatric lupus erythematosus. Clin Rheumatol. 1998;17(2):110–114. doi: 10.1007/BF01452255. [DOI] [PubMed] [Google Scholar]
  36. Kawano M. M., Mihara K., Huang N., Tsujimoto T., Kuramoto A. Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis. Blood. 1995 Jan 15;85(2):487–494. [PubMed] [Google Scholar]
  37. Kiberd B. A. Interleukin-6 receptor blockage ameliorates murine lupus nephritis. J Am Soc Nephrol. 1993 Jul;4(1):58–61. doi: 10.1681/ASN.V4158. [DOI] [PubMed] [Google Scholar]
  38. Kitamura M., Sütö T., Yokoo T., Shimizu F., Fine L. G. Transforming growth factor-beta 1 is the predominant paracrine inhibitor of macrophage cytokine synthesis produced by glomerular mesangial cells . J Immunol. 1996 Apr 15;156(8):2964–2971. [PubMed] [Google Scholar]
  39. Kube D., Platzer C., von Knethen A., Straub H., Bohlen H., Hafner M., Tesch H. Isolation of the human interleukin 10 promoter. Characterization of the promoter activity in Burkitt's lymphoma cell lines. Cytokine. 1995 Jan;7(1):1–7. doi: 10.1006/cyto.1995.1001. [DOI] [PubMed] [Google Scholar]
  40. Lacki J. K., Leszczynski P., Kelemen J., Müller W., Mackiewicz S. H. Cytokine concentration in serum of lupus erythematosus patients: the effect on acute phase response. J Med. 1997;28(1-2):99–107. [PubMed] [Google Scholar]
  41. Lazarus M., Hajeer A. H., Turner D., Sinnott P., Worthington J., Ollier W. E., Hutchinson I. V. Genetic variation in the interleukin 10 gene promoter and systemic lupus erythematosus. J Rheumatol. 1997 Dec;24(12):2314–2317. [PubMed] [Google Scholar]
  42. Lee S. H., Park S. H., Min J. K., Kim S. I., Yoo W. H., Hong Y. S., Park J. H., Cho C. S., Kim T. G., Han H. Decreased tumour necrosis factor-beta production in TNFB*2 homozygote: an important predisposing factor of lupus nephritis in Koreans. Lupus. 1997;6(7):603–609. doi: 10.1177/096120339700600708. [DOI] [PubMed] [Google Scholar]
  43. Lee S., Kaneko H., Sekigawa I., Tokano Y., Takasaki Y., Hashimoto H. Circulating interleukin-16 in systemic lupus erythematosus. Br J Rheumatol. 1998 Dec;37(12):1334–1337. doi: 10.1093/rheumatology/37.12.1334. [DOI] [PubMed] [Google Scholar]
  44. Linker-Israeli M., Quismorio F. P., Jr, Wong D. K., Friou G. J. Serum antibodies to human fetal antigens in patients with systemic lupus erythematosus (SLE). J Immunol. 1980 Mar;124(3):1154–1159. [PubMed] [Google Scholar]
  45. Liu T. F., Jones B. M. Impaired production of IL-12 in systemic lupus erythematosus. I. Excessive production of IL-10 suppresses production of IL-12 by monocytes. Cytokine. 1998 Feb;10(2):140–147. doi: 10.1006/cyto.1997.0268. [DOI] [PubMed] [Google Scholar]
  46. Llorente L., Richaud-Patin Y., Couderc J., Alarcon-Segovia D., Ruiz-Soto R., Alcocer-Castillejos N., Alcocer-Varela J., Granados J., Bahena S., Galanaud P. Dysregulation of interleukin-10 production in relatives of patients with systemic lupus erythematosus. Arthritis Rheum. 1997 Aug;40(8):1429–1435. doi: 10.1002/art.1780400810. [DOI] [PubMed] [Google Scholar]
  47. Llorente L., Zou W., Levy Y., Richaud-Patin Y., Wijdenes J., Alcocer-Varela J., Morel-Fourrier B., Brouet J. C., Alarcon-Segovia D., Galanaud P. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med. 1995 Mar 1;181(3):839–844. doi: 10.1084/jem.181.3.839. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Madaio M. P., Hodder S., Schwartz R. S., Stollar B. D. Responsiveness of autoimmune and normal mice to nucleic acid antigens. J Immunol. 1984 Feb;132(2):872–876. [PubMed] [Google Scholar]
  49. Mehrian R., Quismorio F. P., Jr, Strassmann G., Stimmler M. M., Horwitz D. A., Kitridou R. C., Gauderman W. J., Morrison J., Brautbar C., Jacob C. O. Synergistic effect between IL-10 and bcl-2 genotypes in determining susceptibility to systemic lupus erythematosus. Arthritis Rheum. 1998 Apr;41(4):596–602. doi: 10.1002/1529-0131(199804)41:4<596::AID-ART6>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
  50. Mitamura K., Kang H., Tomita Y., Hashimoto H., Sawada S., Horie T. Impaired tumour necrosis factor-alpha (TNF-alpha) production and abnormal B cell response to TNF-alpha in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol. 1991 Sep;85(3):386–391. doi: 10.1111/j.1365-2249.1991.tb05736.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Mohan C., Adams S., Stanik V., Datta S. K. Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med. 1993 May 1;177(5):1367–1381. doi: 10.1084/jem.177.5.1367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Mok C. C., Lanchbury J. S., Chan D. W., Lau C. S. Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus. Arthritis Rheum. 1998 Jun;41(6):1090–1095. doi: 10.1002/1529-0131(199806)41:6<1090::AID-ART16>3.0.CO;2-6. [DOI] [PubMed] [Google Scholar]
  53. Mosmann T. R., Coffman R. L. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol. 1989;46:111–147. doi: 10.1016/s0065-2776(08)60652-5. [DOI] [PubMed] [Google Scholar]
  54. Nagafuchi H., Suzuki N., Mizushima Y., Sakane T. Constitutive expression of IL-6 receptors and their role in the excessive B cell function in patients with systemic lupus erythematosus. J Immunol. 1993 Dec 1;151(11):6525–6534. [PubMed] [Google Scholar]
  55. Nürnberg W., Haas N., Schadendorf D., Czarnetzki B. M. Interleukin-6 expression in the skin of patients with lupus erythematosus. Exp Dermatol. 1995 Feb;4(1):52–57. doi: 10.1111/j.1600-0625.1995.tb00222.x. [DOI] [PubMed] [Google Scholar]
  56. Ohtsuka K., Gray J. D., Stimmler M. M., Horwitz D. A. The relationship between defects in lymphocyte production of transforming growth factor-beta1 in systemic lupus erythematosus and disease activity or severity. Lupus. 1999;8(2):90–94. doi: 10.1191/096120399678847489. [DOI] [PubMed] [Google Scholar]
  57. Ohtsuka K., Gray J. D., Stimmler M. M., Toro B., Horwitz D. A. Decreased production of TGF-beta by lymphocytes from patients with systemic lupus erythematosus. J Immunol. 1998 Mar 1;160(5):2539–2545. [PubMed] [Google Scholar]
  58. Park Y. B., Lee S. K., Kim D. S., Lee J., Lee C. H., Song C. H. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol. 1998 May-Jun;16(3):283–288. [PubMed] [Google Scholar]
  59. Pelton B. K., Hylton W., Denman A. M. Activation of IL-6 production by UV irradiation of blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol. 1992 Aug;89(2):251–254. doi: 10.1111/j.1365-2249.1992.tb06940.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Spronk P. E., Horst G., Van Der Gun B. T., Limburg P. C., Kallenberg C. G. Anti-dsDNA production coincides with concurrent B and T cell activation during development of active disease in systemic lupus erythematosus (SLE). Clin Exp Immunol. 1996 Jun;104(3):446–453. doi: 10.1046/j.1365-2249.1996.44754.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Spronk P. E., vd Gun B. T., Limburg P. C., Kallenberg C. G. B cell activation in clinically quiescent systemic lupus erythematosus (SLE) is related to immunoglobulin levels, but not to levels of anti-dsDNA, nor to concurrent T cell activation. Clin Exp Immunol. 1993 Jul;93(1):39–44. doi: 10.1111/j.1365-2249.1993.tb06494.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Sturfelt G., Hellmer G., Truedsson L. TNF microsatellites in systemic lupus erythematosus-a high frequency of the TNFabc 2-3-1 haplotype in multicase SLE families. Lupus. 1996 Dec;5(6):618–622. doi: 10.1177/096120339600500611. [DOI] [PubMed] [Google Scholar]
  63. Sturfelt G., Roux-Lombard P., Wollheim F. A., Dayer J. M. Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus. Br J Rheumatol. 1997 Dec;36(12):1283–1289. doi: 10.1093/rheumatology/36.12.1283. [DOI] [PubMed] [Google Scholar]
  64. Symmons D. P. Frequency of lupus in people of African origin. Lupus. 1995 Jun;4(3):176–178. doi: 10.1177/096120339500400303. [DOI] [PubMed] [Google Scholar]
  65. Tesar V., Jirsa M., Jr, Masek Z., Bartůnková J., Stejskalová A., Dostál C., Zabka J., Chábová V., Rysavá R. Solubilní receptory pro cytokiny u renální vaskulitidy a lupoidní nefritidy. Cas Lek Cesk. 1998 May 4;137(9):271–275. [PubMed] [Google Scholar]
  66. Turner D. M., Williams D. M., Sankaran D., Lazarus M., Sinnott P. J., Hutchinson I. V. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997 Feb;24(1):1–8. doi: 10.1111/j.1365-2370.1997.tb00001.x. [DOI] [PubMed] [Google Scholar]
  67. Viallard J. F., Pellegrin J. L., Ranchin V., Schaeverbeke T., Dehais J., Longy-Boursier M., Ragnaud J. M., Leng B., Moreau J. F. Th1 (IL-2, interferon-gamma (IFN-gamma)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol. 1999 Jan;115(1):189–195. doi: 10.1046/j.1365-2249.1999.00766.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Westendorp R. G., Langermans J. A., Huizinga T. W., Elouali A. H., Verweij C. L., Boomsma D. I., Vandenbroucke J. P., Vandenbrouke J. P. Genetic influence on cytokine production and fatal meningococcal disease. Lancet. 1997 Jan 18;349(9046):170–173. doi: 10.1016/s0140-6736(96)06413-6. [DOI] [PubMed] [Google Scholar]
  69. Wilson A. G., Symons J. A., McDowell T. L., McDevitt H. O., Duff G. W. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3195–3199. doi: 10.1073/pnas.94.7.3195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Wilson A. G., de Vries N., Pociot F., di Giovine F. S., van der Putte L. B., Duff G. W. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med. 1993 Feb 1;177(2):557–560. doi: 10.1084/jem.177.2.557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Wilson A. G., di Giovine F. S., Blakemore A. I., Duff G. W. Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. Hum Mol Genet. 1992 Aug;1(5):353–353. doi: 10.1093/hmg/1.5.353. [DOI] [PubMed] [Google Scholar]
  72. Yoshio T., Masuyama J. I., Kohda N., Hirata D., Sato H., Iwamoto M., Mimori A., Takeda A., Minota S., Kano S. Association of interleukin 6 release from endothelial cells and pulmonary hypertension in SLE. J Rheumatol. 1997 Mar;24(3):489–495. [PubMed] [Google Scholar]
  73. al-Janadi M., al-Dalaan A., al-Balla S., al-Humaidi M., Raziuddin S. Interleukin-10 (IL-10) secretion in systemic lupus erythematosus and rheumatoid arthritis: IL-10-dependent CD4+CD45RO+ T cell-B cell antibody synthesis. J Clin Immunol. 1996 Jul;16(4):198–207. doi: 10.1007/BF01541225. [DOI] [PubMed] [Google Scholar]
  74. de Waal Malefyt R., Yssel H., Roncarolo M. G., Spits H., de Vries J. E. Interleukin-10. Curr Opin Immunol. 1992 Jun;4(3):314–320. doi: 10.1016/0952-7915(92)90082-p. [DOI] [PubMed] [Google Scholar]
  75. van der Zee J. M., Miltenburg A. M., Siegert C. E., Daha M. R., Breedveld F. C. Antiendothelial cell antibodies in systemic lupus erythematosus: enhanced antibody binding to interleukin-1-stimulated endothelium. Int Arch Allergy Immunol. 1994;104(2):131–136. doi: 10.1159/000236720. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES